sil0730
New Member
Joined: Dec 22, 2011 13:24:53 GMT -5
Posts: 18
|
Post by sil0730 on Apr 11, 2012 10:05:51 GMT -5
The 4G LTE networks have been growing rapidly across the world providing significant opportunities for companies in the technology sector. "The fastest developing mobile system technology ever" is an entirely IP based network with significantly higher download speeds and higher signal quality. Oppurtunities grow with rapidly expanding 4G LTE networks. I'm investing in VRNG. Do you trade or invest in penny stocks?
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Apr 11, 2012 13:12:25 GMT -5
it depends on the stock. I still hold part of my original positions in aria, dndn, lvlt,ctl and a few others. most i trade out of within a few months to a year. I think ais is going to be a hold i look for it to be bought out within 18 months, because of the nature of pennies it almost impossible to short them and make anything although i did have a bit of luck on ctic.
|
|
sil0730
New Member
Joined: Dec 22, 2011 13:24:53 GMT -5
Posts: 18
|
Post by sil0730 on Apr 13, 2012 18:06:59 GMT -5
Anybody see it! VRNG up $.60 after hours. Something should develope over the week end...wishfully. Raise your hand if you bought it...Smart move
|
|
sil0730
New Member
Joined: Dec 22, 2011 13:24:53 GMT -5
Posts: 18
|
Post by sil0730 on Apr 15, 2012 8:50:53 GMT -5
...wishfully...Just doesn't cut it. A close look at the chart shows it's overbought. Overbought is where the most desirable price moves occur and horrendous corrections happen. Volume last week was 25 million, previous week 50 million, three weeks ago 1.5 million. VRNG closed at $3.59, up from .68 on 01/27/12....catch the wave.
|
|
sil0730
New Member
Joined: Dec 22, 2011 13:24:53 GMT -5
Posts: 18
|
Post by sil0730 on Apr 19, 2012 7:49:10 GMT -5
I like today's intraday chart on VRNG. Two indicators, CCI & MACDline are showing exceptional strength. In my opinion, a pop to $4.50 is rational. The remaining indicators are positive and supportive to suggest my assumption....Catch the wave!
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Apr 30, 2012 9:58:46 GMT -5
Celldex Therapeutics (CLDX)
Celldex focuses on the development, manufacturing, and commercialization of novel therapeutics for human health care primarily in the United States. The company markets Rotarix to treat rotavirus infection. Its lead drug candidate, rindopepimut (CDX-110), is an immunotherapeutic vaccine in Phase III clinical trial to target the tumor-specific molecule, epidermal growth factor receptor variant III, as well as in Phase II clinical trial for the indication of recurrent glioblastoma. The companys other lead drug candidates comprise CDX-011, an antibody-drug conjugate in Phase IIb clinical trial for metastatic breast cancer and melanoma indication; and CDX-1127, a human monoclonal antibody in Phase I clinical trial for the treatment of lymphoma/leukemia and solid tumors.
|
|
sil0730
New Member
Joined: Dec 22, 2011 13:24:53 GMT -5
Posts: 18
|
Post by sil0730 on Apr 30, 2012 12:05:52 GMT -5
VRNG has investors interest. Vringo regains compliance with NYSE Amex continued listing standards. Up today $.37. One might think it's an airline co. This sucker is flying!!
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Apr 30, 2012 13:45:29 GMT -5
please refrain from pumping
|
|
sil0730
New Member
Joined: Dec 22, 2011 13:24:53 GMT -5
Posts: 18
|
Post by sil0730 on Apr 30, 2012 15:59:21 GMT -5
What is wrong with a pump? I see & hear stocks pumped every day. I'm in good company with the business media and the likes of Ben. I'll leave out the superlatives....go VRNG
|
|
ModE98
Administrator
Start Investing admin
Joined: Dec 20, 2010 16:11:39 GMT -5
Posts: 4,441
|
Post by ModE98 on Apr 30, 2012 18:46:48 GMT -5
Message deleted by ModE88.
|
|
ModE98
Administrator
Start Investing admin
Joined: Dec 20, 2010 16:11:39 GMT -5
Posts: 4,441
|
Post by ModE98 on Apr 30, 2012 18:47:09 GMT -5
sil0730 ... Believe what he meant was do not "imbellish" a mentioned stock to the point it appears to be a "pump" as this board does not want to become another Yahoo mayhem board. There is absolutely nothing wrong in presenting a stock here. If there are specific reasons others you believe should consider it, just state the facts. They can decide their own reasons to get excited about it, or not. Yes, please leave out any superlatives so that the post is not misinterpreted as a "pump and " action. Thank you.
ModE (moderator).
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 1, 2012 9:24:14 GMT -5
thanks ModE88
|
|
burger
Junior Member
Joined: Feb 12, 2011 20:34:09 GMT -5
Posts: 143
|
Post by burger on May 3, 2012 12:26:16 GMT -5
I'm still holding on to my ADXS. Hopefully, presenting some results at ASCO in June will be a nice catalyst for this stock. That along with clearing up their financing (they have to be running short on cash at the moment) would go a long way to moving it up. I can wait another month or so. Hopefully, it will be worth it!
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 4, 2012 12:21:47 GMT -5
I am still holding mine also, with pennies it is usually all or nothing and i was betting heavy on this one. actually i might though some more at it and drive down my cost per share
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 4, 2012 13:31:14 GMT -5
NovaBay Pharmaceuticals (NBY):development-stage drug that mimics the mechanism of action of human white blood cells. It's being developed in ophthalmology in eye drop form to treat viral conjunctivitis; in urology to reduce the incidence of urinary catheter blockage and encrustation, as well as associated urinary tract infections; and as a gel to treat impetigo, a contagious skin infection.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 9, 2012 12:14:28 GMT -5
Sunesis Pharma (SNSS). Vosaroxin is a first-in-class anticancer quinolone derivative, or AQD, a class of compounds that has not been used previously for the treatment of cancer. Vosaroxin exerts potent anticancer activity through a mechanism that involves intercalation into DNA and an inhibition of topoisomerase II activity that results in replication-dependent, site-selective double-strand breaks in DNA. The DNA damage induced by vosaroxin is analogous to that of the quinolone antibiotics in bacterial cells.
Topoisomerase II enzymes are essential for the survival of eukaryotic cells. By cleaving and then re-ligating double-strand breaks, they maintain DNA topology during replication and support chromosome condensation, decondensation, and segregation.
Vosaroxin blocks the re-ligation of topoisomerase II-induced double-strand breaks at selective sites in DNA. This leads to G2 arrest and cell death by apoptosis.
Vosaroxin is differentiated chemically and mechanistically from other clinically active topoisomerase II inhibitors. It is not a P-glycoprotein (P-gp) substrate, thereby evading the most common mechanism for multidrug resistance. This may contribute to the vosaroxin activity observed in anthracycline-resistant patients. Other important attributes that differentiate vosaroxin from existing therapies are its targeted DNA damage, p53 family independence, limited distribution to normal tissues relative to anthracyclines, and a more chemically stable molecular structure. These attributes may contribute to vosaroxin's broad therapeutic profile in patients with various tumor types.
The mechanism of action of vosaroxin contrasts with the more promiscuously intercalative tetracyclic core of the anthracyclines, and this may lead to an improved toxicity profile. In addition, anthracyclines are also associated with significant production of reactive oxygen species (ROS), which have been linked to cardiotoxicity. By comparison, the vosaroxin naphthyridine core is less chemically reactive and produces few ROS, potentially reducing the risk of cardiotoxicity.
Currently at 2.69
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 15, 2012 14:01:01 GMT -5
for burger: Advaxis, Inc., (OTCBB: ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, has retired approximately $4.5 million in aggregate convertible debt due on May 12, 2012, October 31, 2012, and January 9, 2013. Existing unconverted debt and interest payments will be settled through a combination of the exchange of the remaining debt for 29.8 million shares of company common stock, the exchange of 19.6 million warrants for shares, the issuance of 2.7 million additional shares, and the cancellation of 5.8 million warrants to Advaxis. As part of this agreement, multiple covenants restricting Advaxis fundraising activities have been waived.
In addition, Advaxis has entered into agreements to raise $1,240,000 via a $500,000 payment from JMJ Financial, and $740,000 from the purchase of Convertible Promissory Notes due one year from the date of issuance this should keep them going for a while
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 16, 2012 15:36:52 GMT -5
ImmunoCellular (IMUC.OB) 5/16/12 pps: $2.70, market cap: $107.48M, is one such company that could be on the way to achieving this.
IMUC is a clinical-stage biotech company based in Los Angeles. The company focuses on the development of new immune-based products in the treatment and diagnosis of brain and other cancers.
After a successful phase I trial was finished, a new phase II trial recently started on the company's lead product candidate, ICT-107, a dendritic cell-based vaccine that targets multiple tumor-associated antigens for glioblastoma, an aggressive form of brain cancer.
This is done by removing dendritic cells from a patient, loading them with the tumor-related antigens, and re-injecting them back into the patient's body to trigger an immune response against cancer cells exhibiting these antigens. An antigen is any substance that causes your immune system to produce antibodies against it.
|
|
burger
Junior Member
Joined: Feb 12, 2011 20:34:09 GMT -5
Posts: 143
|
Post by burger on May 17, 2012 10:41:27 GMT -5
I liked what ADXS did, even if the stock price didn't. I chose to add 20K shares on that day to average down my position. Now, I'll just sit and wait until early June when they present at ASCO.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on May 23, 2012 12:03:38 GMT -5
Discovery Laboratories Inc. (DSCO) introduced not one, but two new products to the market.
Pulmonary surfactant is a lipoprotein that everyone has in their lungs to prevent atelectasis, or alveolar collapse. This lipoprotein usually begins to develop around 26 weeks of gestation, and continues to develop until birth. The reason why this is all relevant is because babies born prematurely, often have poorly developed pulmonary surfactant and have a syndrome known as infant respiratory distress syndrome (RDS). The treatment for RDS is surfactant replacement, but up until this year there have been no synthetic forms of surfactant on the market, only animal derived surfactants. Afectair and Surfaxin are the two products that were approved by the FDA this year. Afectair is a drug delivery product that simplifies the delivery of any inhaled therapies. It is expected to be introduced in the U.S. and European Union later this year. Surfaxin too, is expected to hit the market later this year. Surfaxin is a synthetic form of surfactant, and a recent study showed that synthetic forms of surfactants can be much more cost effective than animal derived surfactants.
|
|
burger
Junior Member
Joined: Feb 12, 2011 20:34:09 GMT -5
Posts: 143
|
Post by burger on Jun 6, 2012 9:59:28 GMT -5
More good results from ADXS at ASCO, still no movement int he price of the stock. Getting pretty frustrated by this one.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jun 7, 2012 15:47:58 GMT -5
Zalicus Inc. (Zalicus):ZLCS, formerly CombinatoRx, is a biopharmaceutical company developing drug candidates with a focus on the treatment of pain and inflammation. The Company has devoted substantially all of its resources to the development of its drug discovery technologies and the research and development of its drug candidates, including conducting preclinical and clinical trials and seeking intellectual property protection for its technology and product candidates. The Company operates in two geographic segments: the United States and Canada. On March 1, 2010, the United States Food and Drug Administration (FDA), approved the New Drug Application for Exalgo (hydromorphone HCl) extended-release tablets, for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time hang in there on adxs when it pops it will be good besides i am to far in
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jun 13, 2012 11:25:46 GMT -5
burger: PRINCETON, N.J., Jun 13, 2012 (BUSINESS WIRE) -- Advaxis, Inc., (ADXS, Trade ), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the publication of preclinical research with ADXS-PSA (ADXS31-142), Advaxis' Lm-LLO immunotherapy targeting the PSA antigen associated with prostate cancer.
This research was conducted in collaboration with Dr. Chandan Guha and his laboratory at Montefiore Medical Center, Bronx, NY. The paper titled "Combined immunotherapy with Listeria monocytogenes-based PSA vaccine and radiation therapy leads to a therapeutic response in a murine model of prostate cancer" by Hannan R, Zhang H, Wallecha A, Singh R, Liu L, Cohen P, Alfieri A, Rothman J, and Guha C., has been e-published ahead of print in the journal Cancer Immunology Immunotherapy.
The objective of the study was to determine if the combination of ADXS-PSA immunotherapy and radiation therapy could improve upon the efficacy of either immunotherapy alone or radiation therapy alone in the treatment of mice bearing PSA-expressing TPSA23 tumors, a preclinical model of prostate cancer.
The study showed:
-- The combination of ADXS-PSA immunotherapy and radiation therapy resulted in complete regression of established tumors in 60% of mice compared to less-than or equal to 10% complete regression in either of the treatments alone.
-- In mice that completely regressed after combination therapy, tumors did not develop upon re-challenge with tumor cells, suggesting the induction of systemic and protective immune memory.
-- In addition, combination therapy resulted in increased induction of PSA-specific T cells in the periphery and an increased infiltration of these cells in the tumor microenvironment.
"ADXS-PSA continues to demonstrate activity in models of prostate cancer, confirming our decision to move this construct into clinical development. The potential synergy of ADXS-PSA and radiotherapy observed in this study suggests that ADXS-PSA might be combined with other therapies that show efficacy in this type of tumor," commented Dr. John Rothman, EVP of Science and Operations at Advaxis. one day it will pop and pop big. going to increase my shares again
|
|
burger
Junior Member
Joined: Feb 12, 2011 20:34:09 GMT -5
Posts: 143
|
Post by burger on Jun 20, 2012 21:59:24 GMT -5
I own about 140K shares of ADXS, and I'm holding. News has been good, and now it seems as though they have enough finances to make it through to 2013 Q1 without having to dilute any further. I just wish they'd get some sort of partnership or something to get the price up.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jun 21, 2012 13:43:57 GMT -5
Chelsea Therapeutics International's (CHTP): Chelsea's lead product, Northera (droxidopa) has been given theOrphan Drug designation by the FDA and was given a nod by the FDA advisory panel (by a vote of 7-1 with one non-vote and one abstention) on February 23rd 2012 for symptomatic neurogenic orthostatic hypotension (also known as Neurogenic OH or NOH) in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy, and pure autonomic failure), dopamine beta hydroxylase deficiency and non-diabetic autonomic neuropathy. Essentially, the targeted patient set has a norepinephrine deficiency
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jun 21, 2012 13:44:54 GMT -5
I am still holding mine too, i sill belive it will be big
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jun 27, 2012 7:57:04 GMT -5
Antares Pharma(atrs): announces positive results from VIBEX MTX usability study The purpose of this study was to conduct a cumulative and summative round of simulated usability testing of the VIBEX MTX device in accordance with FDA draft guidance. The study design was reviewed by the FDA prior to initiation. Fifty individuals representing three user groups participated in this study, including 17 RA patients, 16 lay caregivers and 17 healthcare professionals. All participants in the patient group had been diagnosed with rheumatoid arthritis by a physician. In addition, the patients were screened twice using the Health Assessment 20 Item Disability Scale to determine the extent of hand function impairment of the sort associated with RA patients. Patients with an average HAQ score of 2.0 to 2.5, defined as "severe to very severe" hand function impairment, were enrolled into the study. The results of the study showed that the VIBEX MTX device is safe and effective for intended users, uses and use environments. The validation testing proved the product is easy to learn and safe to use as demonstrated by correct and successful injections.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jul 5, 2012 14:13:53 GMT -5
ok so it is a little bit above my $5.00 limit but i can bend my own rules. OREX:Orexigen has a weight-loss drug called Contrave that could be hitting the market in 2014. As more of these drugs gain approval by the FDA, the market will become more competitive as larger pharmaceuticals try to enter and gain market share in this lucrative market.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jul 10, 2012 14:26:56 GMT -5
OVIT:OncoVista Innovative Therapies, Inc. (OTCBB: OVIT), a biopharmaceutical company engaged in the development and commercialization of targeted cancer therapies, announced today that the US Food and Drug Administration (FDA) granted approval for the Company's investigational new drug (IND) application for its L-nucleoside conjugate (OVI-117) drug candidate. About OVI-117
OVI-117, a derivative of FdUMP/5-FU, is a Thymidylate Synthase (TS -1.39%, news) inhibitor with enhanced pharmacological properties resulting in the retention of efficacy and the reduction of toxicity. It has particular promise for colon, breast, gastric and prostate tumors.
|
|
gambler
Well-Known Member
"the education of a man is never completed until he dies" Robert E. Lee
Joined: Dec 21, 2010 16:39:24 GMT -5
Posts: 1,576
|
Post by gambler on Jul 18, 2012 14:10:13 GMT -5
Teletouch Communications (TLLE.OB): Multiple new distribution agreements were announced last month, a key indication that Teletouch is making headway in securing a dominating presence in the distribution channels of several well-known brands, such as AT&T (T). Also noteworthy to the Teletouch bottom line was settled litigation with T that brought in over $18 million dollars, not a small sum for a still-growing company. The litigation related to certain hardware that the telecom giant was not allowing Teletouch to sell through its channels, but as a result of the settlement the two entities agreed upon another multi-year contract that - since they also agreed to forgo any further litigation - should keep the marriage well intact.
Most significantly, the large settlement sum from T eases the monetary burden for Teletouch as it shifts its core business from providing wireless services to the more profitable one of hardware sales and distribution It is not a bio tech for a change of pace
|
|